Bank of New York Mellon Corp Has $333,000 Stock Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Bank of New York Mellon Corp increased its position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 5.6% during the fourth quarter, Holdings Channel reports. The fund owned 50,660 shares of the company’s stock after acquiring an additional 2,677 shares during the quarter. Bank of New York Mellon Corp’s holdings in Lexeo Therapeutics were worth $333,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in LXEO. Geode Capital Management LLC boosted its position in shares of Lexeo Therapeutics by 86.5% in the third quarter. Geode Capital Management LLC now owns 553,247 shares of the company’s stock worth $5,003,000 after buying an additional 256,635 shares during the period. State Street Corp grew its stake in Lexeo Therapeutics by 29.4% during the 3rd quarter. State Street Corp now owns 253,946 shares of the company’s stock valued at $2,296,000 after acquiring an additional 57,674 shares in the last quarter. Frazier Life Sciences Management L.P. acquired a new position in shares of Lexeo Therapeutics in the 3rd quarter valued at about $11,307,000. Barclays PLC lifted its position in shares of Lexeo Therapeutics by 162.2% in the third quarter. Barclays PLC now owns 50,210 shares of the company’s stock worth $454,000 after purchasing an additional 31,057 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in shares of Lexeo Therapeutics by 18.9% during the third quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock worth $33,997,000 after purchasing an additional 599,203 shares during the period. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $23.00 target price on shares of Lexeo Therapeutics in a research report on Wednesday. Royal Bank of Canada cut their price objective on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday. Chardan Capital reissued a “buy” rating and set a $25.00 price objective on shares of Lexeo Therapeutics in a research report on Tuesday. Finally, Leerink Partners dropped their target price on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research report on Monday, March 24th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $22.80.

Lexeo Therapeutics Stock Down 0.2 %

Shares of LXEO stock opened at $4.10 on Friday. The stock’s 50 day simple moving average is $4.05 and its 200 day simple moving average is $6.58. Lexeo Therapeutics, Inc. has a twelve month low of $2.32 and a twelve month high of $19.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. The company has a market capitalization of $135.57 million, a price-to-earnings ratio of -1.30 and a beta of 3.85.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09. As a group, research analysts predict that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.